BMC Cancer (Feb 2025)

The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma

  • Matthias Schneider,
  • Anna-Laura Potthoff,
  • Yahya Ahmadipour,
  • Valeri Borger,
  • Hans Clusmann,
  • Stephanie E. Combs,
  • Marcus Czabanka,
  • Lasse Dührsen,
  • Nima Etminan,
  • Thomas M. Freiman,
  • Ruediger Gerlach,
  • Florian Gessler,
  • Frank A. Giordano,
  • Eleni Gkika,
  • Roland Goldbrunner,
  • Erdem Güresir,
  • Hussam Hamou,
  • Peter Hau,
  • Sebastian Ille,
  • Max Jägersberg,
  • Naureen Keric,
  • Maryam Khaleghi-Ghadiri,
  • Ralph König,
  • Jürgen Konczalla,
  • Harald Krenzlin,
  • Sandro Krieg,
  • Aaron Lawson McLean,
  • Julian P. Layer,
  • Jens Lehmberg,
  • Vesna Malinova,
  • Bernhard Meyer,
  • Hanno S. Meyer,
  • Dorothea Miller,
  • Oliver Müller,
  • Christian Musahl,
  • Barbara E. F. Pregler,
  • Ali Rashidi,
  • Florian Ringel,
  • Constantin Roder,
  • Karl Rössler,
  • Veit Rohde,
  • I. Erol Sandalcioglu,
  • Niklas Schäfer,
  • Christina Schaub,
  • Nils Ole Schmidt,
  • Gerrit A. Schubert,
  • Clemens Seidel,
  • Corinna Seliger,
  • Christian Senft,
  • Julia Shawarba,
  • Joachim Steinbach,
  • Veit Stöcklein,
  • Walter Stummer,
  • Ulrich Sure,
  • Ghazaleh Tabatabai,
  • Marcos Tatagiba,
  • Niklas Thon,
  • Marco Timmer,
  • Johannes Wach,
  • Arthur Wagner,
  • Christian Rainer Wirtz,
  • Katharina Zeiler,
  • Thomas Zeyen,
  • Patrick Schuss,
  • Rainer Surges,
  • Christine Fuhrmann,
  • Daniel Paech,
  • Matthias Schmid,
  • Yvonne Borck,
  • Torsten Pietsch,
  • Rafael Struck,
  • Alexander Radbruch,
  • Christoph Helmstaedter,
  • Robert Németh,
  • Ulrich Herrlinger,
  • Hartmut Vatter

DOI
https://doi.org/10.1186/s12885-025-13682-3
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Background The discovery of cellular tumor networks in glioblastoma, with routes of malignant communication extending far beyond the detectable tumor margins, has highlighted the potential of supramarginal resection strategies. Retrospective data suggest that these approaches may improve long-term disease control. However, their application is limited by the proximity of critical brain regions and vasculature, posing challenges for validation in randomized trials. Anterior temporal lobectomy (ATL) is a standardized surgical procedure commonly performed in patients with pharmacoresistant temporal lobe epilepsy. Translating the ATL approach from epilepsy surgery to the neuro-oncological field may provide a model for investigating supramarginal resection in glioblastomas located in the anterior temporal lobe. Methods The ATLAS/NOA-29 trial is a prospective, multicenter, multinational, phase III randomized controlled trial designed to compare ATL with standard gross-total resection (GTR) in patients with newly-diagnosed anterior temporal lobe glioblastoma. The primary endpoint is overall survival (OS), with superiority defined by significant improvements in OS and non-inferiority in the co-primary endpoint, quality of life (QoL; “global health” domain of the European organization for research and treatment of cancer (EORTC) QLQ-C30 questionnaire). Secondary endpoints include progression-free survival (PFS), seizure outcomes, neurocognitive performance, and the longitudinal assessment of six selected domains from the EORTC QLQ-C30 and BN20 questionnaires. Randomization will be performed intraoperatively upon receipt of the fresh frozen section result. A total of 178 patients will be randomized in a 1:1 ratio over a 3-year recruitment period and followed-up for a minimum of 3 years. The trial will be supervised by a Data Safety Monitoring Board, with an interim safety analysis planned after the recruitment of the 57th patient to assess potential differences in modified Rankin Scale (mRS) scores between the treatment arms 6 months after resection. Assuming a median improvement in OS from 17 to 27.5 months, the trial is powered at > 80% to detect OS differences with a two-sided log-rank test at a 5% significance level. Discussion The ATLAS/NOA-29 trial aims to determine whether ATL provides superior outcomes at equal patients’ Qol compared to GTR in anterior temporal lobe glioblastoma, potentially establishing ATL as the surgical approach of choice for isolated temporal glioblastoma and redefining the standard of care for this patient population. Trial registration German Clinical Trials Register (DRKS00035314), registered on October 18, 2024.

Keywords